New opportunities for acute decompensated heart failure diagnostics and clinical value of growth factors: VEGF, PDGF-AB, FGF basic, tissue inhibitor of metalloproteinase-1, and lipoprotein-associated phospholipase A2

In structure of mortality, the leading cause of death of adults in economically developed countries is heart disease with heart failure. Early risk stratification before clinical manifestation of decompensated heart failure is relevant and extremely important task. Aim. The study was aimed at searching for new diagnostic biomarkers and predictors of high risk of adverse cardiovascular events and mortality in patients with decompensated heart failure. A total of 206 patients, enrolled in the study, were assigned into 3 groups: group 1 comprised 94 patients with postmyocardial infarction or ischemic remodeling where the prognostic importance of growth factors of VEGf, PDGF-AB, and FGF basic was studied; the diagnostic importance of TIMP-1 was studied in 52 patients with HF NYHA classes II- IV (group 2); and the predictive value of Lp-FLA2 was analyzed in 60 patients with diabetes mellitus type 2 associated with HF NYHA class II (group 3). Receiver operating characteristic (ROC) curves used for assessing the accuracy of predictions revealed high positive predictive values for growth factors VEGF (the area under a curve 0.71+0.05; r=0.000) and FGF basic (0.71+0.05; r=0.000), for PDGF-AB (0.66+0.06; r=0.009). Plasma level of TIMP-1>485.7 ng/mL was found to be an independent, highly sensitive prognostic factor of progression of HF and mortality (specificity of 100%; sensitivity of 80.4%). We found high correlation (r=0.66; p=0.000) between concentration of Lp-FLA2 and a frequency of a stenosis of coronary arteries in patients with type 2 diabetes mellitus (cutoff level of Lp-FLA2 983 ng/mL, sensitivity of 80%; specificity of 100%). Prognostic value of TIMP-1 as an independent marker of risk for progressing of HF and mortality is great and it should be used more widely in cardiology practice. Our study suggests that the levels of growth factors and Lp-FLA2 can be used as candidate markers associated with ischemic dysfunction of the heart, atherosclerosis of coronary arteries, and metabolic disorders. Larger studies are required to verify these findings.

хроническая сердечная недостаточность, биомаркеры, факторы роста, тканевой ингибитор матриксных металлопротеиназ-1, липопротеинассоциированная фосфолипаза А2, chronic heart failure, biomarkers, growth factors, tissue inhibitor of metalloproteinase-1, lipoprotein-associated phospholipase A2

1. Александрова Е.Б. Хроническая сердечная недостаточность у больных гипертонической болезнью и ишемической болезнью сердца: возрастные и гендерные аспекты // Кардиология. - 2013. - № 7. - С. 40-44.

2. Веселовская Н.Г., Чумакова Г.А., Отт А.В. и др. Прогнозирование риска рестеноза коронарных артерий после их стентирования у пациентов с ожирением // Сердце: журнал для практикующих врачей. - 2013. - № 5(73). - С. 305-310.

3. Егорова Е.Н., Мазур В.В., Калинкин М.Н. и др. Взаимосвязь эндотоксемии, факторов системного воспаления и компонентов системы матриксных металлопротеиназ - тканевых ингибиторов металлопротеиназ при ХСН // Сердечная недостаточность. - 2012. - № 4(72). - С. 233-236.

4. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome // Cardiovascular Research. - 2006. - Vol. 69(3). - Р. 636-645.

5. Миклищанская С.В., Власик Т.Н., Хеймец Г.Н. и др. Влияние интенсивной гиполипидемической терапии на концентрацию липопротеинассоциированной фосфолипазы А2 в крови больных ишемической болезни сердца // Кардиология. - 2013. - № 9. - С. 4-11.

6. Соломахина Н.И., Беленков Ю.Н. Прогностическое значение тканевого ингибитора матриксных металлопротеиназ - 1 (TIMP-1) у больных ХСН // Сердечная недостаточность. - 2010. - Т. 5 (61). - С. 281-284.

7. Тепляков А.Т., Болотская Л.Я., Дибиров М.М. и др. Клиникоиммунологические нарушения у больных с постинфарктным ремоделирование левого желудочка с ХСН // Тер. архив. - 2008. - № 11. - С. 52-57.

8. Фомин И.В. Эпидемиология хронической сердечной недостаточности в Российской Федерации // Хроническая сердечная недостаточность. - М.: ГЭОТАР-Медиа, 2010. -С. 7-77.

9. Чумакова Г.А., Веселовская Н.Г, Казаренко А.А. Факторы риска рестенозов после реваскуляризации миокарда у пациентов с метаболическим синдромом и сахарным диабетом 2 типа // Сердце: журнал для практикующих врачей. - 2010. - № 1(51). - С. 14-18.

10. Carmeliet P. Angiogenesis in life, disease and medicine // Nature. - 2005. - Vol. 438. - Р. 932-936.

11. Caslake M.J., Pacrard C.J., Suckling K.E. et al. Lipoprotein-associated phospholipase A2, platelet - activating factor acetylhydrolase: a potential new risk factor for coronary artery disease // Atherosclerosis. - 2000. - Vol. 150. - Р. 413-419.

12. Christian F., Ansel P., Behzad O. FGF23 induces left ventricular hypertrophy // J. Clin. Invest. - 2011. - Vol. 121(11). - Р. 4393-4408.

13. Danesh J., Thompson A., Orfeil et al. Lipoprotein-associated phosphor-lipase A2 and risk of coronary disease stroke and mortality: collaborative analysis of 32 prospective studies // Lancet. - 2010. - № 375. - Р. 1536-1544.

14. Daniels L.B., Laughlin G.A., Sarno M.J. et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study // J. Am. Coll. Cardiol. - 2008. - No. 51. - Р. 913-919.

15. Del Ry S., Morales M.A., Scali M.C. et al. Effect of concomitant oral chronic dipyridamole therapy on inflammatory cytokines in heart failure patients // Clin. Lab. - 2013. - Vol. 59(7-8). -P. 843-849.

16. Gierber Y., Dunlay S.M., Jaffe A.S. et al. Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community // Atherosclerosis. - 2009. -No. 203. - Р. 593-598.

17. Hunt J.M., Aru G.M., Hayden M.R. et al. Induction of oxidative stress and disintegrin metalloproteinase in human heart endstage failure // Am. J. Physiol. Lung Cell Mol. Physiol. - 2002. -Vol. 283(2). - Р. L239-245.

18. Kelly D., Sguire J.B., Khan S.Q. et al. Usefulness of plasma tissue inhibiter of metalloproteinases as markers of prognosis after acute myocardial infarction // Am. J. Cardiol. - 2010. -Vol. 106(4). - Р. 477-482.

19. Liu L., Eisen H.J. Epidemiology of heart failure and scope of the problem // Cardiol. Clin. - 2014. - Vol. 32(1). - P. 1-8.

20. Nicholls S.J., Tuzcu E.M., Kalidindi S. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular untrasound trials // J. Am. Coll. Cardiol. - 2008. - Vol. 52(4). - Р. 255-262.

21. Raichlin E., McConnell P., Bae H. et al. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in transplant patients // Transplantation. - 2008. - Vol. 85. - Р. 963-968.

22. Ridker P.M., Macfadyen J.G., Wolfert R.L. et al. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analisis from the JUPITER Trial // Clin. Chem. - 2012. - Vol. 58. - Р. 877-886.

23. Rodriguez-Vita J., Ruiz-Ortega M., Ruperez M. et al. Endothelin-1, via ETA Receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells // Circ. Res. - 2005. - Vol. 23. -P. 14-19.

24. Venkataraman K., Khurana S., Tai T.C. Oxidative stress in aging-matters of the heart and mind // Int. J. Mol. Sci. - 2013. -Vol. 14(9). - P. 17897-17925.